samedan logo
 
 
spacer
home > ict > winter 2018 > changing ways
PUBLICATIONS
International Clinical Trials

Changing Ways

For many patients across a wide range of therapeutic areas, participation in a clinical trial can provide access to important life-saving medications. However, the efficient conduct of studies has long been complicated by complex protocols, inefficient recruiting methods and logistics that can make participation burdensome, if not impossible. Consequently, numerous trial sponsors, CROs, and clinical services companies are striving to facilitate patient access to studies while also making the trials themselves more patient-centric. In addition to improving recruitment processes and easing the burden of participation, such efforts are largely designed to enhance patient engagement before, during, and after the study.

While the challenges surrounding patient access, retention, and engagement are not new, surmounting these requires new approaches to trial design and administration. Already, some sponsors and CROs are incorporating patient input into study design to align clinical endpoints with patients’ priorities for health outcomes. On the legislative front, citizens and lawmakers in several US states are seeking to pass ‘right to try’ laws intended to enhance access to experimental drugs, especially for terminally ill patients. Nonetheless, such initiatives will not be sufficient unless they are accompanied by efforts that improve the patient experience.

Transportation Resolutions Historically, transportation costs have constituted a very small portion of clinical trial expenses. However, when patients lack reliable transportation, this can lead to noshows and dropouts, which significantly impact study costs and results (1). A National Research Council report identified inadequate transportation as a major contributor to a 30% dropout rate in Phase 3 trials, noting that the problem worsened over the course of lengthy trials (1,2). Factors such as travel distance and intensive trial-related testing schedules are often cited as barriers to participation, especially among patients considered for lengthier trials and the elderly, as well as for those with challenging disease profiles for whom transportation can be very difficult (3).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kurt Mussina brings more than 25 years of international business success to his role at Frenova Renal Research, including a record of leadership and achievement structuring and orchestrating global business development teams in the CRO industry. As Vice President, General Manager, he is responsible for building organisational alignment of functions to drive profit and research success. Kurt earned a Bachelor of Science in chemistry from Montclair State University, US, and received his MBA from Duke University, Fuqua School of Business, US.
spacer
Kurt Mussina
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

York Health Economics Consortium offers an updated training event

Health economics evidence is a key element in much health services research and particularly in health technology assessments, including submissions for NICE single technology appraisals. Identifying economic evidence to inform submissions involves searches in a range of databases and uses a variety of strategies.
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

 
Industry Events

T3: Trials, Tech and Transformation

30-31 May 2018, Raleigh Convention Center, Raleigh, NC

T3 is back for 2018 to provide you with the latest updates and top tips from across the clinical trials landscape. Connecting leading experts, influencers and innovators from pharma, biotech, CROs, patient advocacy groups, academia and beyond, T3 is themeeting place for all stakeholders to voice their questions, connect with peers, and get direct feedback from an expert speaker line-up.And this year, we're in Raleigh.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement